Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer

Instil Bio, Inc. announced the resumption of its Phase 1 clinical trial of ITIL-306 for the treatment of non-small cell lung cancer, ovarian cancer, and renal cell carcinoma.